The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy

European Journal of Pharmacology

Volumn 636, Issue 1-3, 2010, Pages 137-144

  Arora, Mandeep Kumar ^a   Reddy, Krishna ^a   Balakumar, Pitchai ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Diabetes; Fenofibrate; Low dose strategy; Nephropathy; Oxidative stress; Rosiglitazone

Indexed keywords

CREATININE; FENOFIBRATE; GLUCOSE; LIPID; LISINOPRIL; NITROGEN; ROSIGLITAZONE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CREATININE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; KIDNEY; LIPIDS; OXIDATIVE STRESS; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; PROTEINURIA; RATS; THIAZOLIDINEDIONES;

EID: 77952674092     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.002     Document Type: Article

References (63)

1. Abrass C.K. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am. J. Nephrol. 2004, 24:46-53.
2. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974, 20:470.
3. Amann B., Tinzmann R., Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes 2003, 26:2421-2425.
4. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. PPAR dual agonist: are they opening Pandora's box?. Pharmacol. Res. 2007, 56:91-98.
5. Bao Y., Jia R.H., Yuan J., Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007, 80:57-64.
6. Benigni A., Zoja C., Corna D., Zatelli C., Conti S., Campana M., Gagliardini E., Rottoli D., Zanchi C., Abbate M., Ledbetter S., Remuzzi G. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 2003, 14:1816-1824.
7. Bonsnes R.W., Taussky H.H. On the colorimetric determination of creatinine by the Jaffe reaction. J. Biol. Chem. 1945, 158:581-591.
8. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 1973, 19:476-482.
9. Burns K.D. Angiotensin II and its receptors in the diabetic kidney. Am. J. Kidney Dis. 2000, 36:449-467.
10. Buse J.B. Glitazones and heart failure: critical appraisal for the clinicians. Circulation 2003, 108:e57.
11. Cha D.R., Kang Y.S., Han S.Y., Jee Y.H., Han K.H., Han J.Y., Kim Y.S., Kim N.H. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J. Endocrinol. 2004, 183:183-194.
12. Chen Y.J., Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase expression and enhanced renal prostaglandin release. J. Phamacol. Exp. Therap. 2008, 324:658-663.
13. Chen L.L., Zhang J.Y., Wang B.P. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul. Pharmacol. 2006, 4:309-315.
14. Conlon D. Goodbye glitazars?. Br. J. Diabetes Vasc. Dis. 2006, 6:135-137.
15. Connolly S.B., Sadlier D., Kieran N.E., Doran P., Brady H.R. Transcriptome profiling and the pathogenesis of diabetic complications. J. Am. Soc. Nephrol. 2003, 14:S279-S283.
16. Duvillard L., Florentin E., Lizard G., Petit J.M., Galland F., Monier S., Gambert P., Verges B. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003, 26:1540-1544.
17. Ellman G.L. Tissue sulfhydryl groups. Archives Biochem. Biophy. 1959, 82:70-77.
18. Fawcett J.K., Scott E. A rapid and precise method for the determination of urea. J. Clin. Pathol. 1960, 13:156-159.
19. Ferre P. The biology of peroxisome proliferator-activated receptor: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53:543-550.
20. Finco, Duncan Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: a study of 111 cases and a review of related literature. J. Am. Vet. Med. Assoc. 1976, 168:593-601.
21. Flanders K.C., Burmester J.K. Medical applications of transforming growth factor-beta. Clin. Med. Res. 2003, 1:13-20.
22. Forbes J.M., Cooper M.E., Oldfield M.D., Thomas M.C. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:S254-S258.
23. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 2008, 26:77-82.
24. Giunti S., Barit D., Cooper M.E. Mechanisms of diabetic nephropathy role of hypertension. Hypertension 2006, 48:519-526.
25. Guerre-Millo M., Gervois P., Raspe E., Madsen L., Poulain P., Derudas B., Herbert J.M., Winegar D.A., Willson T.M., Fruchart J.C., Berge R.K., Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000, 275:16638-16642.
26. Han S.J., Kang E.S., Hur K.Y., Kim H.J., Kim S.H., Yun C.O., Choi S.E., Ahn C.W., Cha B.S., Kang Y., Lee H.C. Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm. Res. 2008, 70:165-173.
27. Holloway A.C., Petrik J.J., Bruin J.E., Gerstein H.C. Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes. Metab. 2008, 10:763-771.
28. Kakkar R., Mantha S.V., Radhi J., Prasad K., Kalra J. Antioxidant defense system in diabetic kidney: a time course study. Life Sci. 1997, 60:667-679.
29. Kim H.S., Noh J.H., Hong S.H., Hwang Y.C., Yang T.Y., Lee M.S., Kim K.W., Lee M.K. Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Biochem. Biophys. Res. Commun. 2008, 367:623-629.
30. Lee H.S., Song C.Y. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am. J. Nephrol. 2009, 29:62-70.
31. Li J.H., Huang X.R., Zhu H.J., Johnson R., Lan H.Y. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003, 63:2010-2019.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randal R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 265-275.
33. Lyman J.L. Blood urea nitrogen and creatinine. Emerg. Med. Clin. North Am. 1986, 4:223-233.
34. Mauer S.M. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994, 45:612-622.
35. McCarty M.F. Adjuvant strategies for prevention of glomerulosclerosis. Med. Hypotheses 2006, 67:1277-1296.
36. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J. Am. Med. Assoc. 2005, 294:2581-2586.
37. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Analytical Biochem. 1979, 95:351-358.
38. Park I.S., Kiyomoto H., Abboud S.L., Abboud H.E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997, 46:473-480.
39. Park S., Song C.Y., Kim B.C., Hong H.K., Lee H.S. Angiotensin II mediates LDL-induced superoxide generation in mesangial cells. Am. J. Physiol. Renal Physiol. 2003, 285:F909-F915.
40. Park C.W., Kim H.W., Ko S.H., Chung H.W., Lim S.W., Yang C.W., Chang Y.S., Sugawara A., Guan Y., Breyer M.D. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor-α. Diabetes 2006, 55:885-893.
41. Park C.W., Zhang Y., Zhang X., Wu Y., Chen L., Cha D.R., Su D., Hwang M.T., Fan X., Davis L., Striker G., Zheng F., Breyer M., Guan Y. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006, 69:1511-1517.
42. Perrone R.D., Madias N.E., Levey A.S. Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 1992, 38:1933-1953.
43. Phillips A.O., Baboolal K., Riley S., Grone H., Janssen U., Steadman R., Williams J., Floege J. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am. J. Kidney Dis. 2001, 37:400-410.
44. Pitrosch F., Herbrig K., Kinder B., Passauer J., Fisher S., Gross P. Rosiglitazone improves glomerular hyperfilteration, renal endothelial dysfunction and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54:2206-2211.
45. Ravid M., Neumann L., Lishner M. Plasma lipids and progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int. 1995, 47:907-910.
46. Reder, Hartmann Diagnostic and pathophysiological aspects of the determination of kidney function in animals. Zentralbl. Veterinarmed. A 1994, 41:253-267.
47. Remuzzi A., Puntorieri S., Alfano M., Macconi D., Abbate M., Bertani T., Remuzzi G. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Lab. Invest. 1992, 67:572-579.
48. Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J., Narins R.G. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 2000, 11:25-38.
49. Rosario R.F., Sharma P. Lipids and diabetic nephropathy. Curr. Diab. Rep. 2006, 6:455-462.
50. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am. J. Cardiol. 2008, 102:34L-40L.
51. Sohn M., Tan Y., Klein R.L., Jaffa A.A. Evidence for low-density lipoprotein-induced expression of connective tissue growth factor in mesangial cells. Kidney Int. 2005, 67:1286-1296.
52. Spencer M.W., Muhlfeld A.S., Segerer S., Hudkins K.L., Kirk E., LeBoeuf R.C., Alpers C.E. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am. J. Nephrol. 2004, 24:20-31.
53. Steals B., Fruchart J.C. Therapeutic role of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460-2470.
54. Tomohiro T., Kumai T., Sato T., Takeba Y., Kobayashi S., Kimura K. Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci. 2007, 80:1364-1372.
55. Trevisan R., Dodesini A.R., Lepore G. Lipids and renal disease. J. Am. Soc. Nephrol. 2006, 17:S145-S147.
56. Trinder K., Hiraga Y., Nakamura N., Kitajo A., Iinuma F. Determination of glucose in blood using glucose oxidase-peroxidase system and 8-hydroxyquinoline-p-anisidine. Chem. Pharm. Bull. (Tokyo) 1979, 27:568-570.
57. Vaziri N.D., Sato T., Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003, 63:1756-1763.
58. Wang Z., Jiang T., Li J., Proctor G., McManaman J.L., Lucia S., Chua S., Levi M. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005, 54:2328-2335.
59. Watanabe N., Kamei S., Ohkubo A., Yamanaka M., Ohsawa S., Makino K., Tokuda K. Urinary protein as measured with a pyrogallol red-molybdate complex manually and in a hitachi 726 automated analyzer. Clin. Chem. 1986, 32:1551-1554.
60. Wolf G., Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron. Physiol. 2007, 106:26-31.
61. Zeng L., Huang S.M., Cai W.L., Fu P., Zhou L. Effects of rosiglitazone on the expression of beta1, integrin and ICAM-1 in high glucose-induced rat glomerular mesangial cells. Sichuan Da Xue Xue Bao Yi Xue Ban 2006, 37(599-601):610.
62. Zhang H., Saha J., Byun J., Schin M.L., Lorenz M., Kennedy R.T. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolic abnormalities in the amelioration of diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2008, 295:F1071-F1081.
63. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., Striker G.E. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPAR-γ activation. Am. J. Physiol. Ren. Physiol. 2002, 282:F639-F648.